BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kavanagh D, Goodship TH. Atypical hemolytic uremic syndrome, genetic basis, and clinical manifestations. Hematology Am Soc Hematol Educ Program. 2011;2011:15-20. [PMID: 22160007 DOI: 10.1182/asheducation-2011.1.15] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Blom AM, Corvillo F, Magda M, Stasiłojć G, Nozal P, Pérez-Valdivia MÁ, Cabello-Chaves V, Rodríguez de Córdoba S, López-Trascasa M, Okrój M. Testing the Activity of Complement Convertases in Serum/Plasma for Diagnosis of C4NeF-Mediated C3 Glomerulonephritis. J Clin Immunol 2016;36:517-27. [PMID: 27146825 DOI: 10.1007/s10875-016-0290-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
2 Westwood JP, Langley K, Heelas E, Machin SJ, Scully M. Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura. Br J Haematol 2014;164:858-66. [PMID: 24372446 DOI: 10.1111/bjh.12707] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
3 Java A, Atkinson J, Salmon J. Defective complement inhibitory function predisposes to renal disease. Annu Rev Med 2013;64:307-24. [PMID: 23121180 DOI: 10.1146/annurev-med-072211-110606] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
4 Ornstein BW, Atkinson JP, Densen P. The complement system in pediatric systemic lupus erythematosus, atypical hemolytic uremic syndrome, and complocentric membranoglomerulopathies. Curr Opin Rheumatol 2012;24:522-9. [PMID: 22810363 DOI: 10.1097/BOR.0b013e328356896b] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
5 Harris CL, Pouw RB, Kavanagh D, Sun R, Ricklin D. Developments in anti-complement therapy; from disease to clinical trial. Mol Immunol 2018;102:89-119. [PMID: 30121124 DOI: 10.1016/j.molimm.2018.06.008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 10.3] [Reference Citation Analysis]
6 Mao S, Zhang J. Role of complement in glomerular diseases. Journal of Receptors and Signal Transduction 2015;36:319-25. [DOI: 10.3109/10799893.2015.1086882] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
7 Åkesson A, Blom AM, Klintman J, Zetterberg E. Indications of underdiagnosis of atypical haemolytic uraemic syndrome in a cohort referred to the Coagulation Unit in Malmo, Sweden, for analysis of ADAMTS13 2007-2012. Nephrology (Carlton) 2017;22:555-61. [PMID: 27175932 DOI: 10.1111/nep.12818] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
8 Oh J, Oh D, Lee SJ, Kim JO, Kim NK, Chong SY, Huh JY, Baker RI; Korean TTP Registry Investigators. Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura. Blood Res 2019;54:218-28. [PMID: 31730685 DOI: 10.5045/br.2019.54.3.218] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
9 Azukaitis K, Simkova E, Majid MA, Galiano M, Benz K, Amann K, Bockmeyer C, Gajjar R, Meyers KE, Cheong HI, Lange-Sperandio B, Jungraithmayr T, Frémeaux-Bacchi V, Bergmann C, Bereczki C, Miklaszewska M, Csuka D, Prohászka Z, Killen P, Gipson P, Sampson MG, Lemaire M, Schaefer F. The Phenotypic Spectrum of Nephropathies Associated with Mutations in Diacylglycerol Kinase ε. J Am Soc Nephrol 2017;28:3066-75. [PMID: 28526779 DOI: 10.1681/ASN.2017010031] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 5.6] [Reference Citation Analysis]
10 Yamada Y, Abe R, Okano Y, Miyakawa Y. Long-term Eculizumab Treatment Contributes to Recovery from End-stage Renal Disease Caused by Atypical Hemolytic Uremic Syndrome. Intern Med 2017;56:1085-8. [PMID: 28458317 DOI: 10.2169/internalmedicine.56.7862] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
11 Cugno M, Gualtierotti R, Possenti I, Testa S, Tel F, Griffini S, Grovetti E, Tedeschi S, Salardi S, Cresseri D, Messa P, Ardissino G. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Thromb Haemost 2014;12:1440-8. [DOI: 10.1111/jth.12615] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 8.0] [Reference Citation Analysis]
12 Volokhina EB, Westra D, van der Velden TJ, van de Kar NC, Mollnes TE, van den Heuvel LP. Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission. Clin Exp Immunol 2015;181:306-13. [PMID: 25079699 DOI: 10.1111/cei.12426] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
13 Ferluga J, Kouser L, Murugaiah V, Sim RB, Kishore U. Potential influences of complement factor H in autoimmune inflammatory and thrombotic disorders. Mol Immunol 2017;84:84-106. [PMID: 28216098 DOI: 10.1016/j.molimm.2017.01.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
14 Cañigral C, Moscardó F, Castro C, Pajares A, Lancharro A, Solves P, de la Rubia J, Carpio N, Sanz MA. Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome. Ann Hematol 2014;93:1421-2. [PMID: 24306089 DOI: 10.1007/s00277-013-1970-3] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
15 Matar D, Naqvi F, Racusen LC, Carter-Monroe N, Montgomery RA, Alachkar N. Atypical hemolytic uremic syndrome recurrence after kidney transplantation. Transplantation. 2014;98:1205-1212. [PMID: 24933457 DOI: 10.1097/tp.0000000000000200] [Cited by in Crossref: 41] [Cited by in F6Publishing: 19] [Article Influence: 5.9] [Reference Citation Analysis]
16 Liszewski MK, Atkinson JP. Too Much of a Good Thing at the Site of Tissue Injury: The Instructive Example of the Complement System Predisposing to Thrombotic Microangiopathy. Hematology 2011;2011:9-14. [DOI: 10.1182/asheducation-2011.1.9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
17 Salameh H, Abu Omar M, Alhariri A, Kisra S, Qasem A, Abdulhak AB. Adult Post-Kidney Transplant Familial Atypical Hemolytic Uremic Syndrome Successfully Treated With Eculizumab: A Case Report and Literature Review. Am J Ther 2016;23:e1110-5. [PMID: 25486517 DOI: 10.1097/MJT.0000000000000133] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
18 Scully M, Goodship T. How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome. Br J Haematol. 2014;164:759-766. [PMID: 24387053 DOI: 10.1111/bjh.12718] [Cited by in Crossref: 101] [Cited by in F6Publishing: 82] [Article Influence: 12.6] [Reference Citation Analysis]
19 Badiola J, Navarrete-Navarrete N, Sabio JM. Thrombotic microangiopathy in a patient with eosinophilic granulomatosis with polyangiitis: case-based review. Rheumatol Int 2019;39:359-65. [PMID: 30554307 DOI: 10.1007/s00296-018-4228-5] [Reference Citation Analysis]
20 Vernon KA, Cook HT. Complement in glomerular disease. Adv Chronic Kidney Dis 2012;19:84-92. [PMID: 22449345 DOI: 10.1053/j.ackd.2012.02.015] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
21 Contreras E, de la Rubia J, Del Río-Garma J, Díaz-Ricart M, García-Gala JM, Lozano M; Grupo Español de Aféresis. [Diagnostic and therapeutic guidelines of thrombotic microangiopathies of the Spanish Apheresis Group]. Med Clin (Barc) 2015;144:331.e1-331.e13. [PMID: 25433791 DOI: 10.1016/j.medcli.2014.09.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
22 Robson KJ, Clucas D, Filshie R, Nandurkar H. Thrombotic microangiopathy associated with intravenous injection of extended-release oxycodone. BMJ Case Rep 2017;2017:bcr-2017-220977. [PMID: 28716778 DOI: 10.1136/bcr-2017-220977] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
23 Watson R, Lindner S, Bordereau P, Hunze E, Tak F, Ngo S, Zipfel PF, Skerka C, Dragon-durey M, Marchbank KJ. Standardisation of the factor H autoantibody assay. Immunobiology 2014;219:9-16. [DOI: 10.1016/j.imbio.2013.06.004] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
24 Berger BE. The Alternative Pathway of Complement and the Evolving Clinical-Pathophysiological Spectrum of Atypical Hemolytic Uremic Syndrome. Am J Med Sci 2016;352:177-90. [PMID: 27524217 DOI: 10.1016/j.amjms.2016.05.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
25 Kościelska-Kasprzak K, Bartoszek D, Myszka M, Zabińska M, Klinger M. The complement cascade and renal disease. Arch Immunol Ther Exp (Warsz) 2014;62:47-57. [PMID: 24030732 DOI: 10.1007/s00005-013-0254-x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
26 Zimbudzi E. Overcoming technical challenges when treating atypical hemolytic uremic syndrome with therapeutic plasma exchange. Int J Nephrol Renovasc Dis 2013;6:245-8. [PMID: 24277990 DOI: 10.2147/IJNRD.S53074] [Reference Citation Analysis]
27 Sanghera P, Ghanta M, Ozay F, Ariyamuthu VK, Tanriover B. Kidney Diseases Associated With Alternative Complement Pathway Dysregulation and Potential Treatment Options. Am J Med Sci. 2017;354:533-538. [PMID: 29208248 DOI: 10.1016/j.amjms.2017.03.024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
28 Yang S, McGookey M, Wang Y, Cataland SR, Wu HM. Effect of blood sampling, processing, and storage on the measurement of complement activation biomarkers. Am J Clin Pathol 2015;143:558-65. [PMID: 25780008 DOI: 10.1309/AJCPXPD7ZQXNTIAL] [Cited by in Crossref: 46] [Cited by in F6Publishing: 26] [Article Influence: 6.6] [Reference Citation Analysis]
29 Haque A, Cortes C, Alam MN, Sreedhar M, Ferreira VP, Pangburn MK. Characterization of Binding Properties of Individual Functional Sites of Human Complement Factor H. Front Immunol 2020;11:1728. [PMID: 32849614 DOI: 10.3389/fimmu.2020.01728] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
30 Dierickx D, Beke E, Devos T, Delannoy A. The Use of Monoclonal Antibodies in Immune-Mediated Hematologic Disorders. Medical Clinics of North America 2012;96:583-619. [DOI: 10.1016/j.mcna.2012.04.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
31 Raina R, Grewal MK, Radhakrishnan Y, Tatineni V, DeCoy M, Burke LL, Bagga A. Optimal management of atypical hemolytic uremic disease: challenges and solutions. Int J Nephrol Renovasc Dis 2019;12:183-204. [PMID: 31564951 DOI: 10.2147/IJNRD.S215370] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
32 Udagawa T, Motoyoshi Y, Matsumura Y, Takei A, Ariji S, Ito E, Chiga M, Nagasawa M, Morio T, Mizutani S. Effect of eculizumab and recombinant human soluble thrombomodulin combination therapy in a 7-year-old girl with atypical hemolytic uremic syndrome due to anti-factor H autoantibodies. CEN Case Rep 2014;3:110-7. [PMID: 28509254 DOI: 10.1007/s13730-013-0097-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
33 Bagga A, Khandelwal P, Mishra K, Thergaonkar R, Vasudevan A, Sharma J, Patnaik SK, Sinha A, Sethi S, Hari P, Dragon-Durey MA; Indian Society of Pediatric Nephrology. Hemolytic uremic syndrome in a developing country: Consensus guidelines. Pediatr Nephrol 2019;34:1465-82. [PMID: 30989342 DOI: 10.1007/s00467-019-04233-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
34 Ažukaitis K, Loirat C, Malina M, Adomaitienė I, Jankauskienė A. Macrovascular involvement in a child with atypical hemolytic uremic syndrome. Pediatr Nephrol 2014;29:1273-7. [PMID: 24352218 DOI: 10.1007/s00467-013-2713-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
35 Janssen van Doorn K, Dirinck E, Verpooten GA, Couttenye MM. Complement factor H mutation associated with membranoproliferative glomerulonephritis with transformation to atypical haemolytic uraemic syndrome. Clin Kidney J 2013;6:216-9. [PMID: 25006455 DOI: 10.1093/ckj/sfs190] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
36 Soraru J, Isbel N, Wong G, Coates PT, Mantha M, Abraham A, Juneja R, Hsu D, Brown F, Bose B, Mudge D, Carroll R, Kausman J, Hughes P, Barbour T, Durkan A, Mount P, Lee D, Larkins N, Ranganathan D, Lim WH. Baseline characteristics of patients with atypical haemolytic uraemic syndrome (aHUS): The Australian cohort in a global aHUS registry. Nephrology (Carlton) 2020;25:683-90. [PMID: 32378251 DOI: 10.1111/nep.13722] [Reference Citation Analysis]
37 Watson R, Wearmouth E, McLoughlin AC, Jackson A, Ward S, Bertram P, Bennaceur K, Barker CE, Pappworth IY, Kavanagh D, Lea SM, Atkinson JP, Goodship TH, Marchbank KJ. Autoantibodies to CD59, CD55, CD46 or CD35 are not associated with atypical haemolytic uraemic syndrome (aHUS). Mol Immunol 2015;63:287-96. [PMID: 25150608 DOI: 10.1016/j.molimm.2014.07.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
38 Takano T, Elimam H, Cybulsky AV. Complement-mediated cellular injury. Semin Nephrol. 2013;33:586-601. [PMID: 24161043 DOI: 10.1016/j.semnephrol.2013.08.009] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 4.5] [Reference Citation Analysis]
39 Åkesson A, Zetterberg E, Klintman J. At the Cross Section of Thrombotic Microangiopathy and Atypical Hemolytic Uremic Syndrome: A Narrative Review of Differential Diagnostics and a Problematization of Nomenclature: At the Cross Section of TMA and aHUS. Ther Apher Dial 2017;21:304-19. [DOI: 10.1111/1744-9987.12535] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
40 Joseph C, Gattineni J. Complement disorders and hemolytic uremic syndrome. Curr Opin Pediatr 2013;25:209-15. [PMID: 23399570 DOI: 10.1097/MOP.0b013e32835df48a] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
41 Cho HJ, Kim JO, Huh JY, Park Y, Kim MG, Oh D. A case of atypical hemolytic uremic syndrome associated with the c.1273C>T mutation in the complement C3 gene. Blood Res 2016;51:210-3. [PMID: 27722136 DOI: 10.5045/br.2016.51.3.210] [Reference Citation Analysis]
42 Salvadori M, Rosso G, Bertoni E. Complement involvement in kidney diseases: From physiopathology to therapeutical targeting. World J Nephrol 2015; 4(2): 169-184 [PMID: 25949931 DOI: 10.5527/wjn.v4.i2.169] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
43 Takatsuki M, Eguchi S, Yamamoto M, Yamaue H, Takada Y; Japanese Society of Hepato-Biliary-Pancreatic Surgery. The outcomes of thrombotic microangiopathy after liver transplantation: A nationwide survey in Japan. J Hepatobiliary Pancreat Sci 2021. [PMID: 34355533 DOI: 10.1002/jhbp.1032] [Reference Citation Analysis]